Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Evidence synthesis · §5

Dulaglutide in type 2 diabetes mellitus: durability of effect — amendment log

Every change made since protocol registration, with its date and reason.

Document identifier
CEI-ES-121/5
Series
Evidence synthesis
Version
3.1
Published
12 Aug 2025
Last reviewed
12 May 2026
Next review
12 Nov 2027
Identifier
10.71829/cei.syn.121
Certainty
High
Cycle
2025 Q3
Review type
Intervention review
Search executed
24 Jun 2025

Templated review frame. This review question was generated by crossing an indication with a compound for which contributing trials exist. Its prose frame is templated and is shared with other questions of the same shape. Its included studies, its summary of findings and its certainty rating are computed from the underlying records and are not templated. The Institute publishes these questions because the alternative is to leave a question the document set can answer unanswered, and it labels them because the alternative is to present a templated frame as an authored one.

§5Amendment log

Every change made to this review after protocol registration is recorded below with its date and its reason. A change that is not in this log did not happen. The Institute publishes the log in full, including changes that did not alter a conclusion, because a reader cannot judge which changes matter unless all of them are visible.

§5.1Amendment log

Table 9. Amendments to this review since protocol registration.

DateVersionAmendmentRecord
14 Apr 20250.1Protocol registeredThe review protocol was registered with the Institute’s secretariat before the search was executed. No change to the review question was made after registration.
09 Sep 20252.1Study reclassifiedA study previously included was reclassified as ineligible following retrieval of the full report. The quantitative synthesis was re-run without it.
29 Dec 20253.2Analysis method changedThe pooling method was changed from a fixed-effect to a random-effects model following observation of between-study heterogeneity exceeding the pre-specified threshold.
13 Apr 20263.3Comment-period disposition appliedAmendments arising from the disposition of a public comment period were applied. Each amendment is traceable to a numbered submission.
07 Jul 20263.0Certainty rating revisedThe certainty rating for one outcome was revised following the addition of a contributing study. The rationale is recorded in the certainty assessment section.
Current version 3.1, ratified in the 2025 Q3 assessment cycle.

§5.2Clinical study report requests

Table 10. Clinical study reports requested for the contributing trials, and the outcome of each request. Refusals are recorded because a review that does not record them presents the sponsor's disclosure decision as the Institute's own.

TrialRequestedOutcome
AWARD-1116 May 2025No response
REWIND07 Jun 2025Supplied on request
AWARD-708 May 2025Supplied on request
HARMONY-OUTCOMES21 May 2025Supplied on request
AWARD-102 Apr 2025Supplied on request
AWARD-502 Apr 2025No response
AWARD-606 Apr 2025Supplied on request

§5.3Superseded versions

Superseded versions of this review remain published at a stable address, are marked as superseded, and link forward to the current version. The current version links back to each of them. That practice was adopted following a submission that a document cited in the literature must remain retrievable in the form in which it was cited; the reasoning is published on the corrections policy disposition page.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet 2019;394(10193):121–130. doi:10.1016/S0140-6736(19)31149-3 · PMID 31189511

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.